A reduced-carbohydrate and lactose-free formulation for stabilization among hospitalized children with severe acute malnutrition: A double-blind, randomized controlled trial.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
25
08
2018
accepted:
18
01
2019
entrez:
27
2
2019
pubmed:
27
2
2019
medline:
19
9
2019
Statut:
epublish
Résumé
Children with medically complicated severe acute malnutrition (SAM) have high risk of inpatient mortality. Diarrhea, carbohydrate malabsorption, and refeeding syndrome may contribute to early mortality and delayed recovery. We tested the hypothesis that a lactose-free, low-carbohydrate F75 milk would serve to limit these risks, thereby reducing the number of days in the stabilization phase. In a multicenter double-blind trial, hospitalized severely malnourished children were randomized to receive standard formula (F75) or isocaloric modified F75 (mF75) without lactose and with reduced carbohydrate. The primary endpoint was time to stabilization, as defined by the World Health Organization (WHO), with intention-to-treat analysis. Secondary outcomes included in-hospital mortality, diarrhea, and biochemical features of malabsorption and refeeding syndrome. The trial was registered at clinicaltrials.gov (NCT02246296). Four hundred eighteen and 425 severely malnourished children were randomized to F75 and mF75, respectively, with 516 (61%) enrolled in Kenya and 327 (39%) in Malawi. Children with a median age of 16 months were enrolled between 4 December 2014 and 24 December 2015. One hundred ninety-four (46%) children assigned to F75 and 188 (44%) to mF75 had diarrhea at admission. Median time to stabilization was 3 days (IQR 2-5 days), which was similar between randomized groups (0.23 [95% CI -0.13 to 0.60], P = 0.59). There was no evidence of effect modification by diarrhea at admission, age, edema, or HIV status. Thirty-six and 39 children died before stabilization in the F75 and in mF75 arm, respectively (P = 0.84). Cumulative days with diarrhea (P = 0.27), enteral (P = 0.42) or intravenous fluids (P = 0.19), other serious adverse events before stabilization, and serum and stool biochemistry at day 3 did not differ between groups. The main limitation was that the primary outcome of clinical stabilization was based on WHO guidelines, comprising clinical evidence of recovery from acute illness as well as metabolic stabilization evidenced by recovery of appetite. Empirically treating hospitalized severely malnourished children during the stabilization phase with lactose-free, reduced-carbohydrate milk formula did not improve clinical outcomes. The biochemical analyses suggest that the lactose-free formulae may still exceed a carbohydrate load threshold for intestinal absorption, which may limit their usefulness in the context of complicated SAM. ClinicalTrials.gov NCT02246296.
Sections du résumé
BACKGROUND
Children with medically complicated severe acute malnutrition (SAM) have high risk of inpatient mortality. Diarrhea, carbohydrate malabsorption, and refeeding syndrome may contribute to early mortality and delayed recovery. We tested the hypothesis that a lactose-free, low-carbohydrate F75 milk would serve to limit these risks, thereby reducing the number of days in the stabilization phase.
METHODS AND FINDINGS
In a multicenter double-blind trial, hospitalized severely malnourished children were randomized to receive standard formula (F75) or isocaloric modified F75 (mF75) without lactose and with reduced carbohydrate. The primary endpoint was time to stabilization, as defined by the World Health Organization (WHO), with intention-to-treat analysis. Secondary outcomes included in-hospital mortality, diarrhea, and biochemical features of malabsorption and refeeding syndrome. The trial was registered at clinicaltrials.gov (NCT02246296). Four hundred eighteen and 425 severely malnourished children were randomized to F75 and mF75, respectively, with 516 (61%) enrolled in Kenya and 327 (39%) in Malawi. Children with a median age of 16 months were enrolled between 4 December 2014 and 24 December 2015. One hundred ninety-four (46%) children assigned to F75 and 188 (44%) to mF75 had diarrhea at admission. Median time to stabilization was 3 days (IQR 2-5 days), which was similar between randomized groups (0.23 [95% CI -0.13 to 0.60], P = 0.59). There was no evidence of effect modification by diarrhea at admission, age, edema, or HIV status. Thirty-six and 39 children died before stabilization in the F75 and in mF75 arm, respectively (P = 0.84). Cumulative days with diarrhea (P = 0.27), enteral (P = 0.42) or intravenous fluids (P = 0.19), other serious adverse events before stabilization, and serum and stool biochemistry at day 3 did not differ between groups. The main limitation was that the primary outcome of clinical stabilization was based on WHO guidelines, comprising clinical evidence of recovery from acute illness as well as metabolic stabilization evidenced by recovery of appetite.
CONCLUSIONS
Empirically treating hospitalized severely malnourished children during the stabilization phase with lactose-free, reduced-carbohydrate milk formula did not improve clinical outcomes. The biochemical analyses suggest that the lactose-free formulae may still exceed a carbohydrate load threshold for intestinal absorption, which may limit their usefulness in the context of complicated SAM.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02246296.
Identifiants
pubmed: 30807589
doi: 10.1371/journal.pmed.1002747
pii: PMEDICINE-D-18-02996
pmc: PMC6390989
doi:
Substances chimiques
Lactose
J2B2A4N98G
Banques de données
ClinicalTrials.gov
['NCT02246296']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1002747Subventions
Organisme : Medical Research Council
ID : MR/M007367/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nutr J. 2011 Oct 11;10:110
pubmed: 21989455
Ann Paediatr. 1966;206(4):245-57
pubmed: 6012738
Lancet. 2006 Dec 2;368(9551):1992-2000
pubmed: 17141707
East Afr Med J. 2009 Jul;86(7):330-6
pubmed: 20499782
Arch Dis Child. 2015 Mar;100(3):283-7
pubmed: 25421910
J Pediatr. 2016 Jul;174:165-70
pubmed: 27178623
Lancet. 2013 Aug 3;382(9890):452-477
pubmed: 23746776
PLoS Med. 2006 Dec;3(12):e500
pubmed: 17194194
J Pediatr Gastroenterol Nutr. 2018 Jun;66 Suppl 3:S68-S71
pubmed: 29762383
JPEN J Parenter Enteral Nutr. 2013 Mar;37(2):161-70
pubmed: 23264168
Arch Dis Child. 1969 Oct;44(237):593-9
pubmed: 5394500
Bull World Health Organ. 2003;81(4):237-43
pubmed: 12764489
PLoS One. 2012;7(6):e38321
pubmed: 22675542
Lancet Glob Health. 2016 Jul;4(7):e464-73
pubmed: 27265353
Metabolism. 2012 Sep;61(9):1224-30
pubmed: 22386944
J Paediatr Child Health. 2002 Dec;38(6):571-7
pubmed: 12410869
Am J Clin Nutr. 2017 Feb;105(2):494-502
pubmed: 28031190
Am J Clin Nutr. 2016 Nov;104(5):1441-1449
pubmed: 27655441
J Paediatr Child Health. 2017 May;53(5):474-479
pubmed: 28052519
Lancet. 2008 Apr 12;371(9620):1305-7
pubmed: 18406865
Lancet. 2004 Apr 3;363(9415):1110-5
pubmed: 15064029
Q J Med. 1989 May;71(265):441-59
pubmed: 2690177
BMC Pediatr. 2017 Jun 7;17(1):140
pubmed: 28592288
Br J Hosp Med (Lond). 2010 Dec;71(12):686-90
pubmed: 21135765
Pediatr Int. 2013 Feb;55(1):79-84
pubmed: 22978457
J Pediatr. 2011 Feb;158(2):282-7.e1
pubmed: 20843523
Am J Clin Nutr. 2015 Apr;101(4):847-59
pubmed: 25833981
BMC Pediatr. 2017 Apr 26;17(1):112
pubmed: 28446221
Am J Clin Nutr. 1974 Aug;27(8):788-96
pubmed: 4211017
BMC Health Serv Res. 2018 Mar 27;18(1):207
pubmed: 29580238
N Engl J Med. 2013 Jan 31;368(5):425-35
pubmed: 23363496
J Pediatr. 1998 Dec;133(6):789-91
pubmed: 9842046
Nutr Rev. 2016 Jan;74(1):48-58
pubmed: 26578625
Best Pract Res Clin Gastroenterol. 2003 Dec;17(6):943-56
pubmed: 14642859